One study found that 76.3% of PTCL tumor cells and immune cells were double-positive for PD-1 and PD-L1, and that PD-L1 expression was associated with poor prognosis in AITL patients (Kim et al., 2020). This evidence concerns the gene PDCD1 and neoplasm.